Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer

Abroad (travel likely)RecruitingPHASE1

Conditions

Metastatic Malignant Solid Neoplasm · Platinum-Resistant Ovarian High Grade Serous Adenocarcinoma · Unresectable Malignant Solid Neoplasm

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
Mayo Clinic in Florida, Jacksonville, Florida, United States
Contact: Study coordinator (Site Public Contact) · 855-776-0015
Contact: Principal Investigator (Andrea E. Wahner Hendrickson)
Emory University Hospital Midtown, Atlanta, Georgia, United States
Contact: Study coordinator (Site Public Contact) · 888-946-7447
Contact: Principal Investigator (Kristen Starbuck)
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
Contact: Study coordinator (Site Public Contact) · 404-778-1868
Contact: Principal Investigator (Kristen Starbuck)
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Contact: Study coordinator (Site Public Contact) · 877-442-3324
Contact: Principal Investigator (Elizabeth K. Lee)
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Contact: Study coordinator (Site Public Contact) · 855-776-0015
Contact: Principal Investigator (Andrea E. Wahner Hendrickson)
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
Contact: Study coordinator (Site Public Contact) · 412-647-8073
Contact: Principal Investigator (Sarah E. Taylor)

Study leads

Elizabeth K Lee
Principal Investigator
Dana-Farber - Harvard Cancer Center LAO

View source on ClinicalTrials.gov